Aldeyra Therapeutics (ALDX) Net Income towards Common Stockholders (2013 - 2026)

Aldeyra Therapeutics' Net Income towards Common Stockholders history runs 14 years deep, the most recent figure standing at -$3.5 million for Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 80.38% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$34.6 million (up 52.11% YoY) and the FY2025 annual result came in at -$38.5 million, up 34.45% from the prior year.
• Net Income towards Common Stockholders was -$3.5 million for Q1 2026 at Aldeyra Therapeutics, up from -$6.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$3.5 million in Q1 2026 and bottomed at -$41.5 million in Q1 2023.
• A 5-year average of -$16.0 million and a median of -$15.8 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Peak annual rise in Net Income towards Common Stockholders reached 80.52% in 2024, while the deepest fall reached 212.27% in 2024.
• Aldeyra Therapeutics' Net Income towards Common Stockholders stood at -$13.2 million in 2022, then surged by 61.62% to -$5.0 million in 2023, then slumped by 212.27% to -$15.8 million in 2024, then surged by 57.97% to -$6.6 million in 2025, then soared by 47.88% to -$3.5 million in 2026.
• Business Quant data shows ALDX's Net Income towards Common Stockholders at -$3.5 million in Q1 2026, -$6.6 million in Q4 2025, and -$14.0 million in Q3 2025.